MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ALDX — Aldeyra Therapeutics, Inc.
NasdaqAldeyra Therapeutics, Inc.
$1.29
+0.06(+4.88%)
- O
- 1.26
- H
- 1.31
- L
- 1.20
- V
- 1.16M
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ALDX
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMay 2, 2014
Employees6
Stock ExchangeNasdaq
Ticker SymbolALDX
Websitehttps://www.aldeyra.com
Key Financial Statistics
| Market Cap | $72.69M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.07 - $16.70 |
| 52-Week Avg Volume | 643.2K |
| VWAP | $1.25 |
| Transactions | 3,638 |
| Total Recorded Bars | 3,123 days |